Cinética y capacidad neutralizante de los anticuerpos homólogos y ...

Referencias Bibliográficas
159. Nogueira RM, Schatzmayr HG, Miagostovich MP, Cavalcanti SM, de Carvalho R.
Use of MAC-ELISA for evaluation of yellow fever vaccination. Rev Inst Med Trop Sao
Paulo 1992;34(5):447-50.
160. Russell PK, Intavivat A, Kanchanapilant S. Anti-dengue immunoglobulins and
serum beta 1 c-a globulin levels in dengue shock syndrome. J Immunol 1969;102(2):412-
20.
161. Koraka P, Suharti C, Setiati TE, Mairuhu AT, Van Gorp E, Hack CE, et al. Kinetics
of dengue virus-specific serum immunoglobulin classes and subclasses correlate with
clinical outcome of infection. J Clin Microbiol 2001;39(12):4332-8.
162. Pavri KM, Sheikh BH, Ghosh SN, Chodankar VP. Immunoglobulin E in sera of
patients of dengue haemorrhagic fever. Indian J Med Res 1977;66(4):537-43.
163. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection
in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis
1973;128(1):7-14.
164. Bancroft WH, Top FH, Jr., Eckels KH, Anderson JH, Jr., McCown JM, Russell PK.
Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow feverimmune
recipients. Infect Immun 1981;31(2):698-703.
165. Henchal EA, McCown JM, Burke DS, Seguin MC, Brandt WE. Epitopic analysis of
antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am
J Trop Med Hyg 1985;34(1):162-9.
166. Morens DM, Halstead SB. Disease severity-related antigenic differences in dengue
2 strains detected by dengue 4 monoclonal antibodies. J Med Virol 1987;22(2):169-74.
167. Thein S, Aaskov J, Myint TT, Shwe TN, Saw TT, Zaw A. Changes in levels of antidengue
virus IgG subclasses in patients with disease of varying severity. J Med Virol
1993;40(2):102-6.
168. Russell PK, Gould DJ, Yuill TM, Nisalak A, Winter PE. Recovery of dengue-4
viruses from mosquito vectors and patients during an epidemic of dengue hemorrhagic
fever. Am J Trop Med Hyg 1969;18(4):580-3.
169. Kuberski TT, Rosen L. Identification of dengue viruses using complement fixing
antigen produced in mosquitoes. Am J Trop Med Hyg 1977;26(3):538-43.
170. G.Garcia AM, Perez AB, Fonte L, Sierra B, Rodriguez-Roche R, Aguirre E, Fiterre
I, Guzman MG. Antibodies from patients with dengue viral infection mediate cellular
cytotoxicity. J Clin Virol 2006;Sep;37(1):53-7.
171. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S,
et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with
disease severity. J Infect Dis 2000;181(1):2-9.
172. Libraty DH, Endy TP, Houng HSH, Green S, Kalayanarooj S, Suntayakorn S, et al.
Differing influences of virus burden and immune activation on disease severity in
secondary dengue-3 virus infections. J Infect Dis 2002;185(9):1213-21.
173. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S, et al.
Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis
2002;8(12):1474-9.
174. Cologna R, Rico-Hesse R. American genotype structures decrease dengue virus
output from human monocytes and dendritic cells. J Virol 2003;77(7):3929-38.
130